{"DataElement":{"publicId":"2588584","version":"1","preferredName":"Protocol Preventive Intervention Agent Administered Name","preferredDefinition":"the name of the active power or cause (as principle, substance, physical or biological factor, etc.) designed to modify or stop the course of a disease administered according to protocol guidelines, an action plan for a clinical trial.","longName":"PRO_PRE_AGT_ADM_NM","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2588581","version":"1","preferredName":"Protocol Preventive Intervention Agent Administered","preferredDefinition":"information related to the administration of an active power or cause (as principle, substance, physical or biological factor, etc.) designed to modify or stop the course of a disease as prescribed by protocol guidelines, an action plan for a clinical trial.","longName":"PRO_PRE_AGT_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2588576","version":"1","preferredName":"Protocol Preventive Intervention Agent","preferredDefinition":"An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.:An attempt to prevent disease.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C25320:C15843:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27556649-B39B-29E0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-18","modifiedBy":"ONEDATA","dateModified":"2007-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27557471-3F69-2EF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2588582","version":"1","preferredName":"Preventive Intervention Agent Name","preferredDefinition":"the name of a prophylactic agent.","longName":"PREV_AGT_NM","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Aspirin 325mg","valueDescription":"Aspirin 325mg","ValueMeaning":{"publicId":"2588583","version":"1","preferredName":"Aspirin 325mg","longName":"2588583","preferredDefinition":"Aspirin 325mg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2754903E-832C-3705-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2754903E-8346-3705-E044-0003BA3F9857","beginDate":"2006-08-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-18","modifiedBy":"CAMPBELB","dateModified":"2007-01-18","deletedIndicator":"No"},{"value":"Coumadin","valueDescription":"Coumadin (prophylactic dose)","ValueMeaning":{"publicId":"2580721","version":"1","preferredName":"Coumadin (prophylactic dose)","longName":"2580721","preferredDefinition":"a prophylactic dose of the anticoagulant Coumadin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-085E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-08-31","modifiedBy":"CAMPBELB","dateModified":"2006-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2754903E-835B-3705-E044-0003BA3F9857","beginDate":"2006-08-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-18","modifiedBy":"CAMPBELB","dateModified":"2007-01-18","deletedIndicator":"No"},{"value":"Low Molecular Weight Heparin","valueDescription":"Low Molecular Weight Heparin (prophylactic dose)","ValueMeaning":{"publicId":"2580726","version":"1","preferredName":"Low Molecular Weight Heparin (prophylactic dose)","longName":"2580726","preferredDefinition":"a prophylactic dose of the anticoagulant Low Molecular Weight Heparin.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0863-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-08-31","modifiedBy":"CAMPBELB","dateModified":"2006-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2754903E-8370-3705-E044-0003BA3F9857","beginDate":"2006-08-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-18","modifiedBy":"CAMPBELB","dateModified":"2007-01-18","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2754AC96-6EF6-3626-E044-0003BA3F9857","beginDate":"2007-01-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-18","modifiedBy":"ONEDATA","dateModified":"2007-01-18","deletedIndicator":"No"},{"value":"Aspirin, other","valueDescription":"Aspirin, other","ValueMeaning":{"publicId":"2588585","version":"1","preferredName":"Aspirin, other","longName":"2588585","preferredDefinition":"Another dosage amount of acetylsalicylic acid.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2754A2CD-76C2-39D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2754853E-E7E4-340B-E044-0003BA3F9857","beginDate":"2006-08-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-18","modifiedBy":"CAMPBELB","dateModified":"2007-01-18","deletedIndicator":"No"},{"value":"Aspirin 81 mg","valueDescription":"Aspirin 81mg","ValueMeaning":{"publicId":"2580724","version":"1","preferredName":"Aspirin 81mg","longName":"2580724","preferredDefinition":"Aspirin 81mg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0861-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-08-31","modifiedBy":"CAMPBELB","dateModified":"2006-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"406501AA-E73E-544A-E044-0003BA3F9857","beginDate":"2007-12-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-12-03","modifiedBy":"ONEDATA","dateModified":"2007-12-03","deletedIndicator":"No"},{"value":"Topical Oral Analgesic","valueDescription":"Topical Oral Analgesics","ValueMeaning":{"publicId":"3534411","version":"1","preferredName":"Topical Oral Analgesics","longName":"3534411","preferredDefinition":"On the surface of the body.: Oral; of, or relating to, or affecting, or for use in the mouth.: Drugs that reduce pain. These drugs include aspirin, acetaminophen, and ibuprofen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topical","conceptCode":"C13344","definition":"On the surface of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Oral","conceptCode":"C25311","definition":"Of, or relating to, or affecting, or for use in the mouth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Analgesic Agent","conceptCode":"C241","definition":"Compounds that alleviate pain without loss of consciousness.  Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation.  Choice of analgesic may be determined by the type of pain.  These compounds include opioid, non-opioid and adjuvant analgesic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5836E1A-D917-6E19-E040-BB89AD434FC8","latestVersionIndicator":"Yes","beginDate":"2012-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5836E1A-D930-6E19-E040-BB89AD434FC8","beginDate":"2012-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-23","modifiedBy":"ONEDATA","dateModified":"2012-07-23","deletedIndicator":"No"},{"value":"Opiate substitute","valueDescription":"Substitution Opiate","ValueMeaning":{"publicId":"3534412","version":"1","preferredName":"Substitution Opiate","longName":"3534412","preferredDefinition":"The act of putting one thing or person in the place of another.: Functionally related to the poppy (Papaver somniferum) alkaloid morphine, natural or synthetic Opiates have widespread effects in the central nervous system, and on smooth muscle, due to activation of specific delta, mu, and kappa opiate receptors (each controlling different brain functions). Opiates include natural ingredients of the poppy and their derivatives - opium, morphine, codeine, and heroin. Morphine preparations are used as analgesic, sedative, or anxiolytic agent, but are also abused as street drugs. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Substitution","conceptCode":"C54071","definition":"The act of putting one thing or person in the place of another.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Opiate","conceptCode":"C1657","definition":"Functionally related to the poppy (Papaver somniferum) alkaloid morphine, natural or synthetic Opiates have widespread effects in the central nervous system, and on smooth muscle, due to activation of specific delta, mu, and kappa opiate receptors (each controlling different brain functions). Opiates include natural ingredients of the poppy and their derivatives - opium, morphine, codeine, and heroin. Morphine preparations are used as analgesic, sedative, or anxiolytic agent, but are also abused as street drugs. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5836E1A-D93D-6E19-E040-BB89AD434FC8","latestVersionIndicator":"Yes","beginDate":"2012-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5836E1A-D956-6E19-E040-BB89AD434FC8","beginDate":"2012-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-23","modifiedBy":"ONEDATA","dateModified":"2012-07-23","deletedIndicator":"No"},{"value":"Dexamethasone","valueDescription":"Dexamethasone","ValueMeaning":{"publicId":"3028376","version":"1","preferredName":"Dexamethasone","longName":"3028376","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8223B6A1-980B-C0E8-E040-BB89AD43538F","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-19","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5836E1A-D960-6E19-E040-BB89AD434FC8","beginDate":"2012-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-23","modifiedBy":"ONEDATA","dateModified":"2012-07-23","deletedIndicator":"No"},{"value":"Opiate","valueDescription":"Opiate","ValueMeaning":{"publicId":"3534413","version":"1","preferredName":"Opiate","longName":"3534413","preferredDefinition":"Functionally related to the poppy (Papaver somniferum) alkaloid morphine, natural or synthetic Opiates have widespread effects in the central nervous system, and on smooth muscle, due to activation of specific delta, mu, and kappa opiate receptors (each controlling different brain functions). Opiates include natural ingredients of the poppy and their derivatives - opium, morphine, codeine, and heroin. Morphine preparations are used as analgesic, sedative, or anxiolytic agent, but are also abused as street drugs. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Opiate","conceptCode":"C1657","definition":"Functionally related to the poppy (Papaver somniferum) alkaloid morphine, natural or synthetic Opiates have widespread effects in the central nervous system, and on smooth muscle, due to activation of specific delta, mu, and kappa opiate receptors (each controlling different brain functions). Opiates include natural ingredients of the poppy and their derivatives - opium, morphine, codeine, and heroin. Morphine preparations are used as analgesic, sedative, or anxiolytic agent, but are also abused as street drugs. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5836E1A-D96C-6E19-E040-BB89AD434FC8","latestVersionIndicator":"Yes","beginDate":"2012-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5836E1A-D985-6E19-E040-BB89AD434FC8","beginDate":"2012-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-23","modifiedBy":"ONEDATA","dateModified":"2012-07-23","deletedIndicator":"No"},{"value":"Fentanyl patch","valueDescription":"Fentanyl Matrix Transdermal Patch","ValueMeaning":{"publicId":"3534415","version":"1","preferredName":"Fentanyl Matrix Transdermal Patch","longName":"3534415","preferredDefinition":"A transdermal formulation containing the synthetic phenylpiperidine opioid agonist fentanyl, with analgesic activity. Upon topical administration, fentanyl diffuses from the transdermal patch through the skin, is transported via the systemic circulation, and selectively binds to the mu-receptor in the central nervous system (CNS), mimicking the effects of endogenous opiates. Stimulation of the mu-receptor inhibits adenyl cyclase activity, induces opening of G-protein-coupled inwardly rectifying potassium (GIRK) channels, and blocks the opening of N-type voltage-gated calcium channels, resulting in hyperpolarization and reduced neuronal excitability; in addition, neuronal release of neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline may decrease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fentanyl Matrix Transdermal Patch","conceptCode":"C80067","definition":"A transdermal formulation containing the synthetic phenylpiperidine opioid agonist fentanyl, with analgesic activity. Upon topical administration, fentanyl diffuses from the transdermal patch through the skin, is transported via the systemic circulation, and selectively binds to the mu-receptor in the central nervous system (CNS), mimicking the effects of endogenous opiates. Stimulation of the mu-receptor inhibits adenyl cyclase activity, induces opening of G-protein-coupled inwardly rectifying potassium (GIRK) channels, and blocks the opening of N-type voltage-gated calcium channels, resulting in hyperpolarization and reduced neuronal excitability; in addition, neuronal release of neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline may decrease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5836E1A-D992-6E19-E040-BB89AD434FC8","latestVersionIndicator":"Yes","beginDate":"2012-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5836E1A-D9AB-6E19-E040-BB89AD434FC8","beginDate":"2012-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-23","modifiedBy":"ONEDATA","dateModified":"2012-07-23","deletedIndicator":"No"},{"value":"Nonsteroidal Antiinflammatory Drug","valueDescription":"Nonsteroidal Antiinflammatory Drug","ValueMeaning":{"publicId":"2578060","version":"1","preferredName":"Nonsteroidal Antiinflammatory Drug","longName":"2578060","preferredDefinition":"Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain NSAIDs also may inhibit lipoxygenase enzymes or phospholipase C or may modulate T-cell function. (AMA Drug Evaluations Annual, 1994, p 1814-5)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nonsteroidal Antiinflammatory Drug","conceptCode":"C257","definition":"A pharmacological agent that is not a steroid and has potential anti-inflammatory, analgesic, antipyretic and anti-platelet activities. Most nonsteroidal anti-inflammatory drugs (NSAIDs) act by inhibiting the conversion of arachidonic acid to the precursors of prostaglandin and thromboxane by cyclooxygenase enzymes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FDF9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-01","modifiedBy":"ONEDATA","dateModified":"2006-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5836E1A-D9BF-6E19-E040-BB89AD434FC8","beginDate":"2012-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-23","modifiedBy":"ONEDATA","dateModified":"2012-07-23","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2839905","version":"1","preferredName":"Other","longName":"2839905","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"635B8107-2331-1337-E040-BB89AD432C60","latestVersionIndicator":"Yes","beginDate":"2009-02-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5836E1A-D9CA-6E19-E040-BB89AD434FC8","beginDate":"2012-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-23","modifiedBy":"ONEDATA","dateModified":"2012-07-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2754851C-5B61-32BF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-18","modifiedBy":"CAMPBELB","dateModified":"2015-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811835","version":"1","longName":"Melanoma","context":"CTEP"},{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"},{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"},{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"},{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"},{"publicId":"2811950","version":"1","longName":"Multiple Myeloma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CRF Text","type":"Preferred Question Text","description":"Agent","url":null,"context":"CTEP"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"27549C15-95A0-3A7A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-18","modifiedBy":"CAMPBELB","dateModified":"2008-07-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}